TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24396024
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ongoing antihypertensive treatment)
Study: 18381951
Drug: DMXAA (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMXAA (doses of 6 to 4,900 mg/m², administered as a 20-minute i.v. infusion weekly or every 3 weeks)
Study: 19321521
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care consisting of 10 minutes of hand therapy three times a week
Study: 11339782
Drug: No diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No diclofenac suppository (Control)
Study: 2890728
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg APM/kg body weight
Study: 2890728
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg body weight as aspartame (APM)
Study: 27565253
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase support using vaginal progesterone gel (n = 202)
Study: 24002227
Drug: Individual cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive-behavioral therapy (CBT) based on the modified Coping Cat Program
Study: 24002227
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual intervention
Study: 22247123
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg every 12 hours)
Study: 22247123
Drug: Vancomycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (15 mg/kg every 12 hours)
Study: 20674827
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (200 microg daily)
Study: 18235151
Drug: Sarpogrelate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate (300 mg/d)
Study: 23782492
Drug: Nocturnal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal continuous positive airway pressure (CPAP) treatment
Study: 14673984
Drug: Tacrolimus 2
Normalized name: Tacrolimus 200 microgram granules for oral suspension sachet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 2 mg
Study: 14673984
Drug: Tacrolimus 3
Normalized name: Tacrolimus 300 microgram/g cutaneous ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 3 mg
Study: 11166502
Drug: Standard or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard or non-enhanced treatment (control group).
Study: 8996671
Drug: Individual biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual biological factors (age, hand volume, hand thickness)
Study: 1479133
Drug: 1 h
Normalized name: Type 1 H substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 h of morning light treatment (about 7000 lux)
Study: 1479133
Drug: 1 h
Normalized name: Type 1 H substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 h of morning placebo treatment (deactivated negative ion generator)
Study: 6361287
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylprednisolone (1,000-mg bolus and daily thereafter for ten days)
Study: 6361287
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose methylprednisolone (100-mg bolus and daily thereafter for ten days)
Study: 31345170
Drug: Telephone counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone counseling for caregivers and multicomponent therapy for cognitively impaired persons in day-care centers.
Study: 30189000
Drug: Electronic home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electronic home medication review tool (before admission)
Study: 30189000
Drug: Electronic home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electronic home medication review tool (after admission)
Study: 17686105
Drug: Immunotherapy for
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy for allergic rhinoconjunctivitis
Study: 15776297
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg i.v. administered at 1 and 9 hours postoperatively
Study: 15776297
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg i.v.
Study: 9659670
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine application (17.5 mg day‐1)
Study: 9659670
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine application (35 mg day‐1)
Study: 8087519
Drug: 30 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 cisplatin weekly + radiotherapy
Study: 8087519
Drug: 6 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/m2 cisplatin daily + radiotherapy
Study: 2789927
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of oxytocin (0.33 u min‐1)
Study: 29207479
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: MOM (start fortification >50 mL/day) and preterm formula
Study: 22283892
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months daily rifampin (4RMP)
Study: 22283892
Drug: 9 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 9 months daily isoniazid (9INH)
Study: 16389540
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 2 weeks
Study: 15541850
Drug: Rhophylac 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhophylac 300 (300 microg dose) administered either intravenously or intramuscularly
Study: 9372670
Drug: Nebulized DSCG
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized DSCG 20 mg every 6 hours from Day 3 to Day 28
Study: 9372670
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 cc NS) every 6 hours from Day 3 to Day 28
Study: 9372670
Drug: Nebulized DSCG
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized DSCG 20 mg
Study: 9372670
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 cc NS)
Study: 1609045
Drug: Guanfacine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine 0.5 mg daily
Study: 31943843
Drug: In silico
Normalized name: DRESSING,BIATAIN SILICONE ADH FOAM 7X7IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: In silico drug screening for potential inhibitory drug molecules
Study: 26645515
Drug: Moxibustion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion therapy (Group A)
Study: 21233256
Drug: Pharmacotherapy management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy management and/or disease management including motivational interviewing (MI) counseling every 6 months over 2 years
Study: 18274885
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine (SP)
Study: 10922131
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (salmeterol 50 microg twice daily + fluticasone propionate 100 microg twice daily)
Study: 10922131
Drug: Concurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent therapy (salmeterol 50 microg twice daily + fluticasone propionate 100 microg twice daily via separate inhalers)
Study: 31779994
Drug: Shenmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai injection (100 ml/day) for 9.28±3.75 days followed by Shenmai capsule (3.6 g/day) for 30 days in addition to cardiac rehabilitation
Study: 27806972
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) 1315 mg catechins (843 mg EGCG), 4 capsules daily for 12 months
Study: 27806972
Drug: Placebo, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 4 capsules daily for 12 months
Study: 18473339
Drug: Rational-emotive behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational-emotive behavior therapy (REBT)
Study: 18473339
Drug: Pharmacotherapy (fluoxetine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (fluoxetine)
Study: 16026803
Drug: IFN beta-1a,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN beta-1a, 22 or 44 mcg subcutaneously three times weekly during years 3 and 4
Study: 7609864
Drug: B-vitamins (thiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-vitamins (thiamine diphosphate 100 mg, pyridoxsine-HCl 200 mg, cyanocobalamin 20 micrograms, p.o.)
Study: 7609864
Drug: Diclofenac (diclofenac-Na,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (diclofenac-Na, 50 mg, p.o.)
Study: 2147029
Drug: Isradipine, 14.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine, 14.5 mg once daily
Study: 381093
Drug: Antacid (Mylanta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (Mylanta II, 30 ml four times daily and PRN)
Study: 30285054
Drug: Low-dose amitriptyline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amitriptyline (25 mg/d)
Study: 30285054
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator (benztropine mesylate, 1 mg/d)
Study: 25068637
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept 2 mg every 4 weeks for 20 weeks, then as needed (PRN) thereafter.
Study: 25068637
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment every 4 weeks for 20 weeks, then sham thereafter.
Study: 22343361
Drug: 3-5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-5 days of antibiotic treatment (group 1)
Study: 22343361
Drug: 7-10 days
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7-10 days of antibiotic treatment (group 2)
Study: 12195449
Drug: Comprehensive outpatient
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive outpatient rehabilitative treatment for 6 weeks, 6 days a week.
Study: 9783376
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg GTN
Study: 9783376
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg GTN
Study: 30005989
Drug: Silver sulphadiazine
Normalized name: Silver sulphadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulphadiazine cream 10mg/g
Study: 27001317
Drug: Emollient balm
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emollient balm applied twice a day for 28 days
Study: 26313719
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg intravenous hydrocortisone administered during anesthetic induction
Study: 26313719
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hydrocortisone administered)
Study: 17131714
Drug: Dose response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose response control dentifrice (250 ppm F; DD)
Study: 9104712
Drug: Inlay with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inlay with Panavia Ex resin (isthmus width equal to group 3 with lingual and proximal preparation)
Study: 8064017
Drug: Control periods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control periods (before and after drug administration)
Study: 3055922
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg nightly (Stratum 1)
Study: 3055922
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice daily (Stratum 1)
Study: 3055922
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg nightly (Stratum 2)
Study: 3055922
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice daily (Stratum 2)
Study: 31770446
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection (PAI) with extended-release bupivacaine 266 mg and 20 mL of 0.5% bupivacaine hydrochloride
Study: 31770446
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block (ACB) with extended-release bupivacaine 266 mg
Study: 31719005
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C (5 g intravenous before anesthesia induction and 5 g in cardioplegic solution)
Study: 28749549
Drug: Rituximab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (2 biweekly infusions of 1g each)
Study: 11820954
Drug: 2HRZS/4HR plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2HRZS/4HR plus vaccine of Mycobacterium vaccae
Study: 11820954
Drug: 4-6 sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-6 sensitive antituberculous drugs and vaccine of Mycobacterium vaccae
Study: 1249190
Drug: Isocaloric diets
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric diets with at least 50 g of carbohydrate
Study: 28638273
Drug: Nefopam infusion
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam infusion (0.3 mg/kg bolus followed by 65 µg/kg/h infusion)
Study: 28638273
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.3 mg/kg bolus followed by 180 µg/kg/h infusion)
Study: 28638273
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (control group, equal to ketamine infusion)
Study: 26042362
Drug: CYT003 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYT003 (0.3 mg)
Study: 26042362
Drug: CYT003 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYT003 (1 mg)
Study: 26042362
Drug: CYT003 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYT003 (2 mg)
Study: 11072779
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (5 g creatine monohydrate, four times daily for 7 days)
Study: 11072779
Drug: Placebo (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glucose capsules, same number as CS)
Study: 8468527
Drug: High cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cholesterol diet (HC): 320 mg cholesterol/1000 kcal
Study: 27110529
Drug: Ketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.25 mg/kg) with paracetamol (15 mg/kg)
Study: 27110529
Drug: Paracetamol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (15 mg/kg) alone
Study: 17709109
Drug: rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 40 mg/day for 4 weeks
Study: 12370562
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil (FO) 1.8 g of omega‐3 fatty acids x d(‐1)
Study: 12370562
Drug: Isoflavones (ISO)
Normalized name: iso-sulfan blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones (ISO) 120 mg soy isolate x d(‐1)
Study: 10583448
Drug: Prazosin pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin pretreatment (3 mg) plus smoking
Study: 10583448
Drug: Atenolol pretreatment
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol pretreatment (50 mg) plus smoking
Study: 8915027
Drug: Full-mouth disinfection
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth disinfection (scaling and rootplaning in 2 visits within 24 h, tongue brushing with 1% chlorhexidine gel for 1 min, mouth rinsing with 0.2% chlorhexidine solution for 2 min, subgingival irrigation with 1% chlorhexidine gel)
Study: 26595100
Drug: Fasting blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting blood glucose and randomized insulin treatment strategy
Study: 25079933
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg prednisolone daily for 2 years (P-group; n=108)
Study: 19996018
Drug: TEVAR (Thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEVAR (Thoracic Endovascular Aortic Repair) in addition to optimal medical therapy (n=72)
Study: 19996018
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy alone (n=68)
Study: 17664199
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (15 mg x kg(‐1) before infusion of heparin and 15 mg x kg(‐1) after protamine infusion)
Study: 15548814
Drug: Niacin 250
Normalized name: niacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 250 mg
Study: 15548814
Drug: Niacin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (both doses)
Study: 11314677
Drug: 100% daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% daily dose of methadone
Study: 11314677
Drug: 50% daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% daily dose of methadone
Study: 11314677
Drug: Methadone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (both doses)
Study: 25517733
Drug: 360 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 µg TNF-K (3 injections)
Study: 25517733
Drug: TNF-K (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-K (all doses)
Study: 25517733
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with anti-TNF antibody response
Study: 25517733
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without anti-TNF antibody response
Study: 20362199
Drug: Pre-absorption using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-absorption using serotype 9V
Study: 20362199
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccine (PCV) doses
Study: 17845107
Drug: Telephone-administered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered cognitive-behavioral therapy (T-CBT) for 16 weeks
Study: 17845107
Drug: Telephone-administered supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered supportive emotion-focused therapy (T-SEFT) for 16 weeks
Study: 10400054
Drug: Idoxifene 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idoxifene 2.5 mg/day
Study: 10400054
Drug: Idoxifene 5
Normalized name: Idoxene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idoxifene 5 mg/day
Study: 10400054
Drug: Idoxifene 10
Normalized name: Idoxene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idoxifene 10 mg/day
Study: 10400054
Drug: Idoxifene (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idoxifene (all doses)
Study: 7575066
Drug: Epoetin alfa,
Normalized name: EPOETIN ALFA,RECOMBINANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alfa, 150 U/kg, administered subcutaneously three times per week for 6 weeks
Study: 7575066
Drug: Epoetin alfa,
Normalized name: EPOETIN ALFA,RECOMBINANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alfa, 150 U/kg, administered to patients who were originally receiving placebo for 6 weeks
Study: 7575066
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously three times per week for 6 weeks
Study: 27862264
Drug: Every three-hour
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every three-hour oral feeding schedule
Study: 27862264
Drug: Every six-hour
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every six-hour oral feeding schedule
Study: 23286782
Drug: Protein and
Normalized name: Protein and/or protein derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein and Ca drink (500 ml)
Study: 10342804
Drug: Video-enhanced, computer-assisted,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-enhanced, computer-assisted, self-administered interviews (V-CASI)
Study: 2387608
Drug: Preanaesthetic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preanaesthetic medication with atropine and retrobulbar injection of xylocaine
Study: 2387608
Drug: Preanaesthetic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preanaesthetic medication with atropine
Study: 2387608
Drug: Retrobulbar injection
Normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar injection of xylocaine
Study: 2387608
Drug: No preanaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preanaesthetic medication with atropine or retrobulbar block with xylocaine
Study: 30817193
Drug: Biopsy, surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsy, surgical or medical therapy, and longitudinal surveillance
Study: 21830265
Drug: Tailored patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored patient preference intervention including educational and motivational components, simplified dosing regimes, and practical reminders (pill dispensers)
Study: 11755939
Drug: Experimental yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental yoghurt (3 cups daily providing 1 g of plant stanols)
Study: 11755939
Drug: Placebo yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo yoghurt (3 cups daily)